Moderna (NASDAQ: MRNA) and Teladoc Health (NYSE: TDOC) ended 2020 as stock market stars, soaring 434% and 138%, respectively. Which one is more likely to repeat the performance in 2021? Let's use a stock-picking game to find out. It's called Motley Fool CAPS, and it uses the wisdom of crowds to find the best investments. Players predict how stocks will perform versus the S&P 500 Index over a particular time frame. CAPS then rates players based on their performance compared to others. And CAPS rates stocks according to the number of players who are bullish on them. Importantly, the game weighs the opinions of highly rated players more heavily. Here's what CAPS tells us about two of today's most dynamic healthcare companies. Image source: Getty Images. Moderna CAPS rating 3 out of 5 stars What investors might be noticing: Moderna is among the top two players in the coronavirus vaccine market. The company's orders this year represent $18.4 billion in sales. It now is working on a booster shot and expects to make it available this fall. That also represents billions in sales. The company has about two dozen programs in the pipeline. What's holding Moderna back from a better score: Investors still aren't sure if the billions in coronavirus vaccine revenue will be recurrent. If the company confirms that vaccinations will take place annually well into the future, investors likely will become more bullish on the shares. Teladoc CAPS rating 5 out of 5 stars What investors might be noticing: The pandemic offered Teladoc's business -- online medical visits -- a huge boost. It posted full-year revenue growth of 98% to $1 billion. And total visits increased 156% to more than 10 million. The company's outlook for this year is bright. Teladoc said it's seeing "strong momentum" and forecasts full-year 2021 revenue of as much as $2 billion. What could hurt Teladoc's rating: As the pandemic eases, Teladoc must show that its momentum does indeed continue and that patients keep coming back. Investors will also look to see how much last year's acquisition of Livongo adds to Teladoc's growth. If these two areas disappoint, the stock could lose stars. Foolish bottom line Top-starred stocks don't always bring in the biggest gains. Of 450 five-star stocks in CAPS, 25% have produced triple-digit returns over the past year. And of the 437 three-star stocks, 39% have generated triple-digit returns in that time frame. So, if CAPS is our guide, it looks like Moderna is heading for another big year... 10 stocks we like better than Moderna Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.Source